Silence Therapeutics PLC Grant of Share Options to Directors (2721B)
03 April 2017 - 4:01PM
UK Regulatory
TIDMSLN
RNS Number : 2721B
Silence Therapeutics PLC
03 April 2017
Grant of share options to Directors
3 April 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that it has granted share options
("Options") to certain of its executive directors to acquire a
total of 554,597 ordinary shares of 5.0p each in the capital of the
Company ("Ordinary Shares") under the Silence Therapeutics Plc
share option scheme.
.
Director Options Granted Total Number Total Number
of Options of Options
held following held as % of
Grant issued share
capital
Ali Mortazavi,
CEO 242,222 3,970,300 5.7%
David Ellam,
CFO 312,375 512,375 0.7%
These Options have been granted as nil cost options vesting
after a period of three years from grant. The Options are subject
to achievement of certain performance conditions within the three
years from grant, on the basis of 33% vesting for a share price of
GBP1.35, a further 33% vesting for a share price of GBP1.50, and
the final 34% for a share price of GBP1.60. The share price must be
maintained for a period of 30 continuous days. The Options are
exercisable over the period of 10 years from the date of grant.
Claw-back and malus provisions apply.
Following these grants the Company has a total of 6,047,583
share options outstanding representing 8.7% of the existing issued
share capital of the Company.
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1 Details of the person discharging managerial
responsibilities/person closely associated
--------------------------------------------------------
a) Name Ali Mortazavi
------------------------------ ------------------------
2 Reason for the notification
--------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------ ------------------------
b) Initial notification/Amendment Initial notification
------------------------------ ------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--------------------------------------------------------
a) Name Silence Therapeutics Plc
------------------------------ ------------------------
b) LEI N/A
------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--------------------------------------------------------------------------
a) Description of the Options over Ordinary Shares
financial instrument,
type of instrument
ISIN for Silence Therapeutics plc Ordinary
Shares GB00B9GTXM62
Identification code
------------------------- -----------------------------------------------
b) Nature of the transaction Grant of Options under the Silence Therapeutics
Plc Share Option Plan
------------------------- -----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 242,222
------------------------- -----------------------------------------------
d) Aggregated information 242,222 Options
Nil cost
* Aggregated volume
* Price
------------------------- -----------------------------------------------
e) Date of the transaction 31 March, 2017
------------------------- -----------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------- -----------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
------------------------------------------------------------
a) Name David Ellam
------------------------------ ----------------------------
2 Reason for the notification
------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------ ----------------------------
b) Initial notification/Amendment Initial notification
------------------------------ ----------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
------------------------------------------------------------
a) Name Silence Therapeutics plc
------------------------------ ----------------------------
b) LEI N/A
------------------------------ ----------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
------------------------------------------------------------
a) Description of the Options over Ordinary Shares
financial instrument,
type of instrument
------------------------------ ----------------------------
Identification code ISIN for Silence Therapeutics
plc Ordinary Shares GB00B9GTXM62
------------------------- ---------------------------------
b) Nature of the transaction Grant of Options under the
Silence Therapeutics Plc
Share Option Plan
------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 312,375
------------------------- ---------------------------------
d) Aggregated information 312,375 Options
Nil cost
* Aggregated volume
* Price
------------------------- ---------------------------------
e) Date of the transaction 31 March 2017
------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
------------------------- ---------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Canaccord Genuity Limited (Nominated Tel: +44 (0)20
Adviser and Joint Broker) 7523 8350
Henry Fitzgerald-O'Connor/Emma
Gabriel
Peel Hunt LLP (Joint Broker) Tel: +44 (0)20
James Steel/Oliver Jackson 7418 8900
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHZLLFBDZFZBBQ
(END) Dow Jones Newswires
April 03, 2017 02:01 ET (06:01 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024